LINK CELL THERAPIES

Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital to tackle one of the greatest challenges in cancer cell therapy - the development of safe and effective CAR T agents for patients with solid tumors. Our unique logic-gate technology enables a new level of precision required for the safe deployment of CAR T beyond current indications. Link's AND-gate CAR Ts require co-expression of cancer targets to drive cell cytotoxicity, thereby providing greater specificity for tumor than what has been achieved to date with existing logic-gate technologies. Combined with additional platforms under development, we are advancing a suite of exciting therapeutic programs that promise to unlock the potential of CAR T therapy across multiple, important cancer indications including solid tumors and certain hematologic cancers.

Also known as: Link Cell Therapies, Inc

Primary location: San Carlos United States